Kogieleum Naidoo
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Kogieleum Naidoo | |
|---|---|
| Occupation(s) | Researcher, Academic |
| Academic background | |
| Alma mater | University of Kwazulu-Natal |
| Academic work | |
| Discipline | tuberculosis-HIV research |
| Institutions | CAPRISA |
Kogieleum Naidoo is a South African scientist, researcher and academic at University of KwaZulu-Natal. Her research work has a focus on the HIV & AIDS infection with focus advancing care for individuals affected by Tuberculosis and AIDS.
Education
[edit]Kogieleum Naidoo has a MBChB in Medicine and Surgery.[1]
She obtained her PhD from University of KwaZulu-Natal: Durban, within the period of February, 2012 to 14 April 2016.[2]
Career
[edit]Kogieleum Naidoo has worked in various capactites from academic, research, and administrative positions.
University of KwaZulu-Natal: Durban
[edit]- Department of Obstetrics and Gynaecology, Pregnancy Hypertension Research Unit -1994
- Clinical Investigator – Paediatric Transmission of AIDS (Petra) Department of Obstetrics and Gynaecology - 1996 - 2000
- Clinical investigator – South African Intrapartum Nevirapine (SAINT) Study (Department of Obstetrics and Gynaecology) - 1999 - 2000[2]
King Edward VIII Hospital: Durban
[edit]- Medical Intern - 1993 - 1994
- Medical Officer (Department of Paediatrics) - 1995 -1996
- Medical Officer (Department of Medicine, University of KwaZulu-Natal) - 2001[2]
Centre for the AIDS Program of Research in South Africa(CAPRISA)
[edit]- Project Director (START study and CAPRISA AIDS Treatment Programme) - 2005
- Head (Treatment Research Programme) - 2007 - 31/10/2024
- Deputy Director and Head of eThekwini CAPRISA Research Clinic (ECRS) - present[3]
Publications
[edit]- Recurrent Subclinical Tuberculosis Among Antiretroviral Therapy–Accessing Participants: Incidence, Clinical Course, and Outcomes [4]
- The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience[5]
- Clinical evaluation of SARS-CoV-2 rapid antigen tests during the Omicron wave in South Africa[6]
Recognition
[edit]- Inaugurated as members of the Academy of Science of South Africa (ASSAf)[7]
- She was the recipient of the Outstanding Female Scientist Prize in 2023[8]
- In 2023, she was elected as an African Academy of Sciences Fellow[2]
References
[edit]- ^ "Professor Kogieleum Naidoo, MBChB, PhD | The AAS". aasciences.africa. Retrieved 2025-08-15.
- ^ a b c d "ORCID". orcid.org. Retrieved 2025-08-15.
- ^ "Kogie Naidoo". The Conversation. 2020-07-13. Retrieved 2025-08-15.
- ^ "Recurrent Subclinical Tuberculosis Among Antiretroviral Therapy–Accessing Participants: Incidence, Clinical Course, and Outcomes".
- ^ Naidoo, Kogieleum; Perumal, Rubeshan; Cox, Helen; Mathema, Barun; Loveday, Marian; Ismail, Nazir; Omar, Shaheed Vally; Georghiou, Sophia B.; Daftary, Amrita; O'Donnell, Max; Ndjeka, Norbert (September 2024). "The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience". The Lancet. Infectious Diseases. 24 (9): e559 – e575. doi:10.1016/S1473-3099(24)00144-0. ISSN 1474-4457. PMID 38527475.
- ^ "Clinical evaluation of SARS-CoV-2 rapid antigen tests during the Omicron wave in South Africa".
- ^ "UKZN NdabaOnline". ndabaonline.ukzn.ac.za. Archived from the original on 2023-01-31. Retrieved 2025-08-15.
- ^ "Professor Kogieleum Naidoo receives the Outstanding Female Scientist Prize". EDCTP. Retrieved 2025-08-15.
| Authority control databases: Academics |
|---|
 | This article needs additional or more specific categories. (August 2025) |